Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial.

Xiao-Feng XieQiu-Yi ZhangJia-Yi HuangLi-Ping ChenXiao-Feng LanXue BaiLin SongShui-Ling XiongSi-Jia GuoCai-Wen Du

Published in: Breast cancer research and treatment (2022)

Pyrotinib plus trastuzumab and chemotherapy offered a promising option with manageable safety profile for heavily pre-treated HER2-positive MBC, especially for those without liver or/and lung metastases.

Keyphrases

epidermal growth factor receptor
metastatic breast cancer
tyrosine kinase
advanced non small cell lung cancer
locally advanced
endothelial cells
open label
clinical trial
induced pluripotent stem cells
rectal cancer
chemotherapy induced
pluripotent stem cells